A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients with High-Risk Classical Hodgkin Lymphoma

Type of Cancer

Phase

Division (Location)

Study ID

NCT#

Brief Description
A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients with High-Risk Classical Hodgkin Lymphoma

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.